Immunovant, Inc. (IMVT) Stock Profile — Insider Trades & Financials

Net Income-$110.6M

EPS$-2.04

Market Cap$5.0B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Eric Venker

CEO & Executive Director

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjÃ¶grenâs disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Founded: 2018
Employees: 362
Headquarters: New York, New York, United States

⚡

Core Efficiency

ROE?

-11.22%

ROA?

-10.51%

D/E Ratio?

0.07

📊

Profitability Ratios

Current Ratio?

15.74

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

May 8, 2026 (in 29 days)

Quarterly Report (10-Q) — Based on filing pattern

May 8, 2026

Predicted10-Q

Feb 6, 2026

10-QQ3 20264d after period end

Nov 10, 2025

10-QQ2 20267d after period end

Aug 11, 2025

10-QQ1 20267d after period end

May 29, 2025

10-KQ4 20256d after period end

Feb 6, 2025

10-QQ3 20256d after period end

Nov 7, 2024

10-QQ2 20256d after period end

Aug 6, 2024

10-QQ1 20257d after period end

May 29, 2024

10-KQ4 20247d after period end

Loading company sections...

Immunovant, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness